Annexon, INC 10-Q quarterly reports

Annexon, Inc. reported a significant increase in net loss and R&D expenses for Q3 2025, while advancing its lead clinical programs and extending its cash runway into late Q1 2027.

Annexon, Inc. reported a significant increase in net losses and R&D expenses in Q2 2025, driven by advanced clinical trials, while projecting its cash runway into Q4 2026 and signaling a need for substantial future financing.

Annexon, a biopharmaceutical company, announced its Q1 2025 financial results, showcasing increased R&D spending and progress in its clinical programs for Guillain-Barr Syndrome (GBS), Geographic Atrophy (GA), and autoimmune indications.

Annexon Inc. reports a net loss of $34.8 million for the third quarter of 2024, while highlighting progress in its clinical programs and financial position.

Annexon, a clinical-stage biopharmaceutical company, announced its second quarter 2024 results, highlighting progress in its key clinical programs and financial position.

Annexon Inc. released its 10-Q filing for the quarter ended March 31, 2024, detailing financial results and providing updates on its clinical programs.